Core B is under the direction of Dan Bellissimo, PhD with important additional input by Ken Friedman, MD. This core serves a number of important functions including 1) sample acceptance and central processing; 2) adding blood center tracking labels for registration purposes of the BCW Diagnostics Laboratory. The de-identified labels on these samples were put in place by the individual clinical centers. The sample testing for VWF phenotyping is done in the Hemostasis Laboratory directed by Dr. Friedman. They are NOT batched by design so that the results obtained on these samples are obtained in the same manner as if a patient sample was referred to the laboratory. When results are completed, reviewed, and signed out the results are automatically transferred to the Investig8 Database. DNA sequencing is of two types. The first is direct, PCR-based sequencing of the coding region of the VWF gene followed by capillary gel analysis. This function was transferred to Milwaukee from Boston during year 4 of the prior cycle. Not only are there the internal standard controls set in place for all testing in the clinical labs, but Core A has repetitive aliquots of normal, borderline, moderate and moderately severe VWD plasma that are used to assure the QG for the PPG study. Next Gen sequencing has been added to this core function and will be used in Projects 1 and 3. While the cost and equipment needs for Next Gen sequencing are rapidly coming down, this is included in Corte B so that we can centrally direct the quality and costs that will be required by the PPG. We anticipate one center in North America (either University of Toronto or Medical College of Wisconsin) and one in Manchester, UK. These two site must be carefully cross standardized so that data output is identical. The reason for the second site within the EU is because of the system developed for these samples by the MCMDM-1 VWD that does not enable samples to leave the Countries of the participating partners.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Program Projects (P01)
Project #
Application #
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Bloodcenter of Wisconsin, Inc.
United States
Zip Code
Obser, T; Ledford-Kraemer, M; Oyen, F et al. (2016) Identification and characterization of the elusive mutation causing the historical von Willebrand Disease type IIC Miami. J Thromb Haemost 14:1725-35
Hawke, Lindsey; Bowman, Mackenzie L; Poon, Man-Chiu et al. (2016) Characterization of aberrant splicing of von Willebrand factor in von Willebrand disease: an underrecognized mechanism. Blood 128:584-93
Ozel, A B; McGee, B; Siemieniak, D et al. (2016) Genome-wide studies of von Willebrand factor propeptide identify loci contributing to variation in propeptide levels and von Willebrand factor clearance. J Thromb Haemost 14:1888-98
Flood, Veronica H; Christopherson, Pamela A; Gill, Joan Cox et al. (2016) Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States. Blood 127:2481-8
Baumgartner, C K; Mattson, J G; Weiler, H et al. (2016) Targeting Factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice. J Thromb Haemost :
Haberichter, Sandra L (2015) von Willebrand factor propeptide: biology and clinical utility. Blood 126:1753-61
Chen, Junmei; Hinckley, Jesse D; Haberichter, Sandra et al. (2015) Variable content of von Willebrand factor mutant monomer drives the phenotypic variability in a family with von Willebrand disease. Blood 126:262-9
Goodeve, A C (2015) Hemophilia B: molecular pathogenesis and mutation analysis. J Thromb Haemost 13:1184-95
Avila, M L; Lee, K-J; Bouskill, V et al. (2015) Acquired von Willebrand syndrome in paediatric patients with congenital heart disease: challenges in the diagnosis and management of this rare condition. Haemophilia 21:e89-92
Deforest, M; Grabell, J; Albert, S et al. (2015) Generation and optimization of the self-administered bleeding assessment tool and its validation as a screening test for von Willebrand disease. Haemophilia 21:e384-8

Showing the most recent 10 out of 97 publications